AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer

E. Jensen-Jarolim*, H. J. Bax, R. Bianchini, S. Crescioli, T. R. Daniels-Wells, D. Dombrowicz, E. Fiebiger, H. J. Gould, S. Irshad, J. Janda, D. H. Josephs, F. Levi-Schaffer, L. O’Mahony, G. Pellizzari, M. L. Penichet, F. Redegeld, F. Roth-Walter, J. Singer, E. Untersmayr, L. VangelistaS. N. Karagiannis

*Corresponding author for this work

Research output: Journal article (peer-reviewed)Journal article

51 Citations (Scopus)


While desired for the cure of allergy, regulatory immune cell subsets and nonclassical Th2-biased inflammatory mediators in the tumour microenvironment can contribute to immune suppression and escape of tumours from immunological detection and clearance. A key aim in the cancer field is therefore to design interventions that can break immunological tolerance and halt cancer progression, whereas on the contrary allergen immunotherapy exactly aims to induce tolerance. In this position paper, we review insights on immune tolerance derived from allergy and from cancer inflammation, focusing on what is known about the roles of key immune cells and mediators. We propose that research in the field of AllergoOncology that aims to delineate these immunological mechanisms with juxtaposed clinical consequences in allergy and cancer may point to novel avenues for therapeutic interventions that stand to benefit both disciplines.

Original languageEnglish
Pages (from-to)328-340
Number of pages13
JournalAllergy: European Journal of Allergy and Clinical Immunology
Issue number2
Publication statusPublished - Feb 2018
Externally publishedYes


  • allergooncology
  • allergy
  • cancer
  • oncoimmunology
  • tolerance

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer'. Together they form a unique fingerprint.

Cite this